Antiestrogens and their therapeutic applications in breast cancer and other diseases

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 217-232

  Ali, Simak ^a   Buluwela, Laki ^a   Coombes, R Charles ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

breast cancer; cancer prevention; estrogen; selective estrogen receptor modulators (SERMs)

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; ARZOXIFENE; BAZEDOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN CITRATE; TOREMIFENE;

ARTICLE; BINDING AFFINITY; BONE DENSITY; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATARACT; CHOLESTEROL BLOOD LEVEL; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN ACTIVITY; HEART PROTECTION; HORMONE STRUCTURE; HOT FLUSH; HUMAN; MENSTRUAL IRREGULARITY; NONHUMAN; OSTEOPOROSIS; OVARY CYST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BREAST; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTORS, ESTROGEN;

EID: 79551584513     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-052209-100305     Document Type: Article

References (99)

1. Kamangar F, Dores GM, Anderson WF. 2006. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24:2137-50
2. Jemal A, Siegel R, Ward E, et al. 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59:225-49
3. Ali S, Coombes RC. 2002. Endocrine-responsive breast cancer and strategies for combatting resistance. Nat. Rev. Cancer 2:101-12
4. Fisher CR, Graves KH, Parlow AF, et al. 1998. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc. Natl. Acad. Sci. USA 95:6965-70
5. Lubahn DB, Moyer JS, Golding TS, et al. 1993. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. USA 90:11162-66
6. Krege JH, Hodgin JB, Couse JF, et al. 1998. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. USA 95:15677-82
7. Oz OK, Hirasawa G, Lawson J, et al. 2001. Bone phenotype of the aromatase deficient mouse. J. Steroid Biochem. Mol. Biol. 79:49-59
8. Windahl SH, Andersson G, Gustafsson JA. 2002. Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol. Metab. 13:195-200
9. Riggs BL, Khosla S, Melton LJ 3rd. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23:279-302
10. Rossouw JE, AndersonGL,Prentice RL, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-33
11. Kannel WB, Hjortland MC, McNamara PM, et al. 1976. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. 85:447-52
12. Nathan L, Chaudhuri G. 1997. Estrogens and atherosclerosis. Annu. Rev. Pharmacol. Toxicol. 37:477-515
13. Barrett-ConnorE,GradyD.1998. Hormone replacement therapy,heart disease, and other considerations. Annu. Rev. Public Health 19:55-72
14. Walton C, Godsland IF, Proudler AJ, et al. 1993. The effects of the menopause on insulin sensitivity, secretion and elimination in nonobese, healthy women. Eur. J. Clin. Invest. 23:466-73
15. Harman SM, Naftolin F, Brinton EA, et al. 2005. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann. NY Acad. Sci. 1052:43-56
16. Barrett-Connor E. 2007. Hormones and heart disease in women: the timing hypothesis. Am. J. Epidemiol. 166:506-10
17. Gusberg SB, Kardon P. 1971. Proliferative endometrial response to theca-granulosa cell tumors. Am. J. Obstet. Gynecol. 111:633-43
18. Creasman WT. 2002. Estrogen and cancer. Gynecol. Oncol. 86:1-9
19. Pike MC, Pearce CL, Wu AH. 2004. Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379-91
20. Russo J, Russo IH. 1987. Development of the Human Mammary Gland, pp. 67-93. New York: Plenum
21. Bocchinfuso WP, Korach KS. 1997. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary Gland Biol. Neoplasia 2:323-34
22. Couse JF, Korach KS. 1999. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 20:358-417
23. Hennighausen L, Robinson GW. 2005. Information networks in the mammary gland. Nat. Rev. Mol. Cell Biol. 6:715-25
24. Weigelt B, Reis-Filho JS. 2009. Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 6:718-30
25. Perou CM, Sorlie T, Eisen MB, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747-52
26. Allen E, Doisy EA. 1923. An ovarian hormone: preliminary report on its localization, extraction and partial purification and action in test animals. JAMA 81:819-23
27. Lacassagne A. 1936. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer 27:217-25
28. Kelsey JL, Gammon MD, John EM. 1993. Reproductive factors and breast cancer. Epidemiol. Rev. 15:36-47
29. Rosner B, Colditz GA. 1996. Nurses' Health Study: log-incidence mathematical model of breast cancer incidence. J. Natl. Cancer Inst. 88:359-64
30. Simpson ER, Clyne C, Rubin G, et al. 2002. Aromatase-a brief overview. Annu. Rev. Physiol. 64:93-127
31. 1990. Breast cancer and combined oral contraceptives: results from a multinational study. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Br. J. Cancer 61:110-19
32. Chlebowski RT, Hendrix SL, Langer RD, et al. 2003. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289:3243-53
33. Clarke RB, Howell A, Potten CS, et al. 1997. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57:4987-91
34. Albertson DG. 2008. Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat. Genet. 40:821-22
35. Khan SA, Rogers MA, Khurana KK, et al. 1998. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst. 90:37-42
36. Shoker BS, Jarvis C, Clarke RB, et al. 1999. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am. J. Pathol. 155:1811-15
37. Harper MJ, Walpole AL. 1966. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212:87
38. Jordan VC. 2003. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2:205-13
39. Lippman M, Bolan G, Huff K. 1976. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36:4595-601
40. Nicholson RI, Golder MP. 1975. The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur. J. Cancer 11:571-79
41. Jordan VC. 1976. Effect of tamoxifen (ICI 46474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 12:419-24
42. Early Breast Cancer Trialists' Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-717
43. Fisher B, Dignam J, Bryant J, et al. 1996. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 88:1529-42
44. Kedar RP, Bourne TH, Powles TJ, et al. 1994. Effects of tamoxifen on uterus and ovaries of post-menopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-21
45. Kristensen B, Ejlertsen B, Dalgaard P, et al. 1994. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol. 12:992-97
46. Love RR, Mazess RB, Barden HS, et al. 1992. Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. N. Engl. J. Med. 326:852-56
47. Rutqvist LE, Mattsson A. 1993. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J. Natl. Cancer Inst. 85:1398-406
48. Costantino JP, Kuller LH, Ives DG, et al. 1997. Coronary heart disease mortality and adjuvant tamoxifen therapy. J. Natl. Cancer Inst. 89:776-82
49. Cuzick J, Powles T, Veronesi U, et al. 2003. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300
50. Fisher B, Costantino JP, Wickerham DL, et al. 2005. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 97:1652-62
51. Ettinger B, Black DM, Mitlak BH, et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-45
52. Cummings SR, Eckert S, Krueger KA, et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189-97
53. Barrett-Connor E, Mosca L, Collins P, et al. 2006. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355:125-37
54. Vogel VG, Costantino JP, Wickerham DL, et al. 2010. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev. Res. 3:696
55. Jensen EV, Jordan VC. 2003. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9:1980-89
56. Howell A. 2006. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer 13:689-706
57. Howell A, Robertson JF, Abram P, et al. 2004. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 22:1605-13
58. Chia S, Gradishar W, Mauriac L, et al. 2008. Double-blind, randomized placebo controlled trial of fulves-trant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 26:1664-70
59. Robertson JF, Llombart-Cussac A, Rolski J, et al. 2009. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J. Clin. Oncol. 27:4530-35
60. Jensen EV, Jacobsen HI. 1962. Basic guides to the mechanism of estrogen action. Rec. Prog. Horm. Res. 18:387-414
61. Toft D, Gorski J. 1966. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. USA 55:1574-81
62. Green S, Walter P, Kumar V, et al. 1986. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134-39
63. Greene GL, Gilna P, Waterfield M, et al. 1986. Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150-54
64. Chawla A, Repa JJ, Evans RM, et al. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-70
65. Kuiper GG, Enmark E, Pelto-Huikko M, et al. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93:5925-30
66. Pace P, Taylor J, Suntharalingam S, et al. 1997. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J. Biol. Chem. 272:25832-38
67. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19:833-42
68. Prall OW, Rogan EM, Musgrove EA, et al. 1998. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell Biol. 18:4499-508
69. Fullwood MJ, Liu MH, Pan YF, et al. 2009. An oestrogen-receptor-alpha- bound human chromatin interactome. Nature 462:58-64
70. Carroll JS, Meyer CA, Song J, et al. 2006. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38:1289-97
71. Eeckhoute J, Carroll JS, Geistlinger TR, et al. 2006. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 20:2513-26
72. Lacroix M, Leclercq G. 2004. About GATA3, HNF3A, and XBP1, three genes coexpressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol. Cell Endocrinol. 219:1-7
73. Lonard DM, Lanz RB, O'Malley BW. 2007. Nuclear receptor coregulators and human disease. Endocr. Rev. 28:575-87
74. Metivier R, Huet G, Gallais R, et al. 2008. Dynamics of estrogen receptor-mediated transcriptional activation of responsive genes in vivo: apprehending transcription in four dimensions. Adv. Exp. Med. Biol. 617:129-38
75. Nettles KW, Greene GL. 2005. Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 67:309-33
76. Glass CK, Rosenfeld MG. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121-41
77. Stallcup MR, Kim JH, Teyssier C, et al. 2003. The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J. Steroid Biochem. Mol. Biol. 85:139-45
78. Xu J, Liao L, Ning G, et al. 2000. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl. Acad. Sci. USA 97:6379-84
79. Xu J, Qiu Y, DeMayo FJ, et al. 1998. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922-25
80. Webb P, Nguyen P, Kushner PJ. 2003. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J. Biol. Chem. 278:6912-20
81. Shang Y, Brown M. 2002. Molecular determinants for the tissue specificity of SERMs. Science 295:2465-68
82. Rosenfeld MG, Lunyak VV, Glass CK. 2006. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20:1405-28
83. Lavinsky RM, Jepsen K, Heinzel T, et al. 1998. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 95:2920-25
84. Jepsen K, Hermanson O, Onami TM, et al. 2000. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753-63
85. Keeton EK, Brown M. 2005. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol. Endocrinol. 19:1543-54
86. Girault I, Lerebours F, Amarir S, et al. 2003. Expression analysis of estrogen receptor alpha coregula-tors in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9:1259-66
87. Green KA, Carroll JS. 2007. Oestrogen-receptor-mediated transcription and the influence of cofactors and chromatin state. Nat. Rev. Cancer 7:713-22
88. Kurebayashi J, Otsuki T, Kunisue H, et al. 2000. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin. Cancer Res. 6:512-18
89. Girault I, Bieche I, Lidereau R. 2006. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54:342-51
90. Myers E, Fleming FJ, Crotty TB, et al. 2004. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br. J. Cancer 91:1687-93
91. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. 2004. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263-74
92. Kirkegaard T, McGlynn LM, Campbell FM, et al. 2007. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 13:1405-11
93. Ciana P, Raviscioni M, Mussi P, et al. 2003. In vivo imaging of transcriptionally active estrogen receptors. Nat. Med. 9:82-86
94. Forbes JF, Cuzick J, Buzdar A, et al. 2008. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet. Oncol. 9:45-53
95. Thurlimann B, Keshaviah A, Coates AS, et al. 2005. A comparison of letrozole and tamoxifen in post-menopausal women with early breast cancer. N. Engl. J. Med. 353:2747-57
96. Coombes RC, Kilburn LS, Snowdon CF, et al. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559-70
97. Hartman J, Strom A, Gustafsson JA. 2009. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 74:635-41
98. Sparano JA, Paik S. 2008. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26:721-28
99. Hoskins JM, Carey LA, McLeod HL. 2009. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9:576-86